EACH: A Randomised Phase II Study Evaluating the Safety and Anti-tumour Activity of the Combination of Avelumab and Cetuximab Relative to Avelumab Monotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Cancer
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2018
At a glance
- Drugs Avelumab (Primary) ; Cetuximab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms EACH
- 03 Aug 2018 Status changed from not yet recruiting to recruiting.
- 02 Jul 2018 Planned initiation date changed from 1 Apr 2018 to 1 Jul 2018.
- 16 Apr 2018 New trial record